MTOR and colorectal carcinoma: Conversely, they may be detected in CRC patients whose tumor cells are more sensitive to mechanistic Target of Rapamycin (mTOR) inhibitors, such as everolimus and rapamycin; however, these interactions have only been studied at a clinical trial level [57,59].